Software for entry level trace analysis and visualisation will incorporate a range of adaptable analysis features to import, analyse and identify individual and multiple markers from trace samples
Nonlinear Dynamics has undertaken a large scale development programme to evolve a new biomarker discovery product range.
This will see the launch of multiple biomarker products to form a robust and scalable solution for the analysis of mass spectrometry and capillary electrophoresis trace data.
It will incorporate a range of new powerful analytical tools for biomarker discovery, predictive modelling and data processing.
John Spreadbury, group sales and marketing director of Nonlinear Dynamics, and CEO of Nonlinear USA, commented: "The fields of drug discovery, biomedical research and pharmacogenomics are developing around the use of biomarkers in accordance with new FDA guidelines.
"The result is that many pharma and biotech companies have reconfigured their research models to incorporate biomarker functionality.
"However at present, widespread implementation of this technique is hampered by the lack of accurate, hardware independent software commercially available to researchers.
"In developing a new biomarker range, Nonlinear is applying its considerable experience and expertise in mining and analysing data from multiple applications.
"Our outstanding technical portfolio underlines the adaptability of our development processes to construct an innovative and targeted research platform specifically aimed at biomarker discovery".
The first release from this development programme will be a medium throughput analysis tool aimed at the academic market.
Set for launch in Q3 2005, Phoretix Biomarker represents a highly usable and flexible software solution for entry level trace data analysis and visualisation.
This will incorporate a range of adaptable analysis features to import, analyse and identify individual and multiple markers from trace samples.
This is achieved through an automated m/z picking algorithm to distinguish particular peaks of interest, while eliminating sample noise.
Spectra can be visualised using a variety of different graphical formats, including stacking and spectral overlay, as well as simulated gel maps.
Comparative visual analysis across multiple samples enables rapid discovery of disparate features for later identification.
Phoretix Biomarker further extends these capabilities with neighbour-joining and UPGMA hierarchical clustering algorithms.
Philippe Bogard, strategic marketing manager of Nonlinear Dynamics, added: "Single protein biomarkers with clinically relevant predictive power are very rare and often lack the sensitivity and specificity required for effective research.
"By applying multiple data-handling and visualisation options, users can identify and review data from multiple markers with increased confidence.
"Marker data can then be queried, validated and classified via a range of database options.
"This represents a considerable improvement over single marker statistics, and a breakthrough for any lab conducting biomarker discovery."
